GAL-101
Asset
Small molecule amyloid oligomer pan-inhibitor preventing neurotoxic oligomer formation
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- APP
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Geographic atrophy of the macula
Phase 2, Recruiting, NCT06659549, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.